Skip to main content

CareDx, Inc. (CDNA)

NASDAQ: CDNA · IEX Real-Time Price · USD
72.24
+1.24 (1.75%)
After-hours:Oct 15, 2021 4:12 PM EDT
71.00
-0.08 (-0.11%)
At close: Oct 15, 4:00 PM
Market Cap3.74B
Revenue (ttm)253.60M
Net Income (ttm)-8.95M
Shares Out52.22M
EPS (ttm)-0.18
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume498,390
Open72.29
Previous Close71.08
Day's Range70.47 - 72.29
52-Week Range45.96 - 99.83
Beta0.65
AnalystsStrong Buy
Price Target107.33 (+51.2%)
Est. Earnings DateOct 28, 2021

About CDNA

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup S...

IndustryBiotechnology
IPO DateJul 17, 2014
CEOPeter Maag
Employees456
Stock ExchangeNASDAQ
Ticker SymbolCDNA
Full Company Profile

Financial Performance

In 2020, CareDx's revenue was $192.19 million, an increase of 51.25% compared to the previous year's $127.07 million. Losses were -$18.71 million, -14.81% less than in 2019.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for CareDx stock is "Strong Buy." The 12-month stock price forecast is 107.33, which is an increase of 51.17% from the latest price.

Price Target
$107.33
(51.17% upside)
Analyst Consensus: Strong Buy

News

CareDx to Report Third Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

2 days ago - GlobeNewsWire

AlloSure, the First dd-cfDNA in Heart and Kidney Transplantation, Launches for Lung Transplant Patients

AlloSure Significantly Improves Management of High-Risk Lung Transplant Patients AlloSure Significantly Improves Management of High-Risk Lung Transplant Patients

4 days ago - GlobeNewsWire

CareDx Extends Leadership in Multimodality Transplant Care with KidneyCare Validation Publication

Multicenter Study Validates AlloMap and Demonstrates the Complementary Value with AlloSure for Detecting Rejection Multicenter Study Validates AlloMap and Demonstrates the Complementary Value with AlloS...

2 weeks ago - GlobeNewsWire

CareDx Continues to Fight for Innovation in Transplantation

False Advertising Lawsuit Against Natera is Set to Go to Trial

2 weeks ago - GlobeNewsWire

CareDx Presents Latest Data on AlloSeq Portfolio at ASHI 2021

AlloSeq to be featured in 8 scientific abstracts at ASHI conference AlloSeq to be featured in 8 scientific abstracts at ASHI conference

2 weeks ago - GlobeNewsWire

COVID 19 Stocks -- Vaccines, Diagnostics, or Treatments?

Which subset of the COVID-19 healthcare market will outperform over the next year?

Other symbols:GILDNVAX
1 month ago - The Motley Fool

CareDx Showcases Leadership in Global Transplantation at ESOT 2021

CareDx announces the launch of AlloSeq cfDNA Research Service and demonstrates global leadership at ESOT with six abstracts and a symposium CareDx announces the launch of AlloSeq cfDNA Research Service ...

1 month ago - GlobeNewsWire

CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates

CareDx (CDNA) delivered earnings and revenue surprises of 120.00% and 9.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

CareDx Reports 77% Revenue Growth for Second Quarter of 2021 and Increases Full Year Revenue Guidance

SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

2 months ago - GlobeNewsWire

CareDx Launches ACROBAT Study to Potentially Change Care Paradigm for Stem Cell Transplant Patients

ACROBAT is the prospective multi-center study of AlloHeme, to study the potential of relapse surveillance for stem cell transplant patients ACROBAT is the prospective multi-center study of AlloHeme, to ...

2 months ago - GlobeNewsWire

CareDx (CDNA) Earnings Expected to Grow: Should You Buy?

CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Apple, Array Tech, Vertex Pharma and More Tuesday Afternoon Analyst Calls

With the trading day more than halfway over, the broad markets were rallying after the carnage on Monday.

2 months ago - 24/7 Wall Street

CareDx to Report Second Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

3 months ago - GlobeNewsWire

CareDx Transplant Patient App, AlloCare, Expands Access to the Majority of Transplant Patients

AlloCare launches in Android Play Store, and is now available on both iOS and Android for all transplant patients AlloCare launches in Android Play Store, and is now available on both iOS and Android fo...

3 months ago - GlobeNewsWire

CareDx CEO Reg Seeto to Present at AAKP 4th Annual Policy Summit

Reg Seeto will present on technology that enables transplant patient care at the AAKP 2021 Summit Reg Seeto will present on technology that enables transplant patient care at the AAKP 2021 Summit

3 months ago - GlobeNewsWire

CareDx to Participate in Raymond James 2021 Human Health Innovation Conference

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

4 months ago - GlobeNewsWire

CareDx congratulates Hannah Valantine for her State of the Art Lecture at ATC on Transplant Equity

Valantine's ATC Presentation Highlights the Role of AlloMap and AlloSure on Inclusive Research and Development Valantine's ATC Presentation Highlights the Role of AlloMap and AlloSure on Inclusive Resea...

4 months ago - GlobeNewsWire

CareDx Presents Landmark KOAR-1000 Data, Demonstrating Higher 1-Year Graft Survival and Reduction in Biopsies through...

KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 patients enrolled KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 pati...

4 months ago - GlobeNewsWire

CareDx Presents Groundbreaking AlloSure® Data at the 2021 American Transplant Congress

Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure Transplant physicians to present 40 scienti...

4 months ago - GlobeNewsWire

CareDx Advances Artificial Intelligence in Transplantation

Partnership with OrganX to develop decision support systems Partnership with OrganX to develop decision support systems

4 months ago - GlobeNewsWire

APA, Bloom Energy, NetApp and More Thursday Afternoon Analyst Calls

With the trading day about halfway over, the markets were sliding, with the tech sector getting the worst of it.

Other symbols:BENTAPAPAAVBBLDEENPH
4 months ago - 24/7 Wall Street

CareDx Starts Enrollment in MAPLE, a Multi-modal, Multi-center, Prospective Study of LiverCare

Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recipients Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recipients

4 months ago - GlobeNewsWire

CareDx Announces Strategic Minority Investment in Miromatrix

Participation in Series C and Research Partnership to Advance Development of Bioengineered Transplantable Organs Participation in Series C and Research Partnership to Advance Development of Bioengineere...

4 months ago - GlobeNewsWire

CareDx to Participate in AAKP and George Washington University Global Summit on Kidney Disease Innovations

CareDx to share innovations in donor-derived cell-free DNA (dd-cfDNA) and patient engagement CareDx to share innovations in donor-derived cell-free DNA (dd-cfDNA) and patient engagement

5 months ago - GlobeNewsWire

This Under-the-Radar Healthcare Company Quietly Surged During the Pandemic

CareDx just posted 76% year-over-year revenue growth for the first quarter and raised its 2021 guidance.

Other symbols:EXASGH
5 months ago - The Motley Fool